Lamotrigine Emerging as a Driver of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An 8-Year Retrospective Study.

Autor: Glahn JZ; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, United States., Almeida MN; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, United States., Kochen A; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, United States., Noel O; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, United States., Stogner V; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, United States; Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany., Hsia HC; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, United States., Savetamal A; Department of Surgery, Connecticut Burn Center, Bridgeport Hospital, Bridgeport, CT, United States. Electronic address: alisa.savetamal@bpthosp.org.
Jazyk: angličtina
Zdroj: Burns : journal of the International Society for Burn Injuries [Burns] 2024 Nov; Vol. 50 (8), pp. 2114-2123. Date of Electronic Publication: 2024 Jul 20.
DOI: 10.1016/j.burns.2024.07.006
Abstrakt: Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent severe manifestations of a potentially life-threatening spectrum defined by a desquamating rash of the skin and mucous membranes. This study was prompted by the observed increase in the off-label use of lamotrigine as a causal agent in SJS/TEN in our regional burn center.
Methods: A retrospective cohort of 48 patients presenting to the Connecticut Burn Center from 2015-2022 with suspicion for SJS/TEN were reviewed for age, sex, causative drug, presenting symptoms, hospital course, biopsy confirmation, length of stay, comorbidities, and 30-day mortality. Descriptive statistical analysis was conducted to identify trends in causative agent, clinical presentation, and mortality.
Results: Thirty patients in our cohort received a final diagnosis of SJS/TEN. While antibiotics remain the most frequent cause of SJS/TEN across the study period (33.3 %, n = 10), the incidence of cases attributable to lamotrigine increased from 1 case between 2015 and 2018 (6.7 %) to 6 cases between 2019 and 2022 (40 %). In 2020 alone, 50 % of all cases were attributable to lamotrigine (n = 4). Of the patients where lamotrigine was implicated, 71.4 % (n = 5) were prescribed lamotrigine for off-label use in the treatment of non-bipolar mood disorders. The average lamotrigine-associated SJS/TEN patient was younger (p < 0.001), had fewer comorbidities, and was more likely to be female than the general SJS/TEN population.
Conclusion: Off-label use of lamotrigine is emerging as a major driver of SJS/TEN with notable changes in patient demographics. Further research is necessary to understand how changing trends in the patient population will impact clinical course and optimal management.
Competing Interests: Declaration of Competing Interest The authors report no funding sources or conflict of interest concerning the materials or methods used in this study or the findings specified in this study.
(Copyright © 2024 Elsevier Ltd and International Society of Burns Injuries. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: